
Tarsus Pharmaceuticals (TARS) Stock Forecast & Price Target
Tarsus Pharmaceuticals (TARS) Analyst Ratings
Bulls say
Tarsus Pharmaceuticals is attractive because XDEMVY is delivering exceptional commercial momentum, with 3Q26 sales of $194.6MM, up 64% year over year, and cumulative net sales now above $1B on more than one million bottles dispensed since launch. Management’s raised FY26 guidance to $715-730MM, alongside record prescriptions, about 20% growth in daily prescribers, and retreatment near 20%, suggests expanding physician adoption and durable demand rather than a one-time launch spike. The outlook is further supported by a cash balance of $309.6MM, a broadening pipeline with TP-04 and TP-05 Phase II topline data on track for 1H27, and added upside from gildeuretinol and IRX-101 acquisitions.
Bears say
Tarsus Pharmaceuticals is vulnerable to a concentrated product-risk profile, as XDEMVY is the main commercial driver and any emergence of a safety issue could quickly undermine adoption, physician confidence, and revenue durability. Its growth thesis also faces launch slowdown as penetration nears peak, while pricing pressure from IRA negotiation or most-favored-nation policy could compress margins and limit the profitability of its ophthalmology franchise. Beyond the core launch, competition in Demodex blepharitis and Stargardt disease, limited exclusivity for gildeuretinol, and potential delays in pipeline programs such as NORTHSTAR and COMFORT increase execution risk and weaken the case for sustained fundamental upside.
This aggregate rating is based on analysts' research of Tarsus Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Tarsus Pharmaceuticals (TARS) Analyst Forecast & Price Prediction
Start investing in Tarsus Pharmaceuticals (TARS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Tarsus Pharmaceuticals (TARS) Forecast
Tarsus Pharmaceuticals (TARS) Analyst Forecast & Price Prediction
Start investing in Tarsus Pharmaceuticals (TARS)
Order type
Buy in
Order amount
Est. shares
0 shares